Fuzheng Jiedu granules against disease progression among high-risk adults with non-severe COVID-19: a multicenter retrospective cohort study
Qiaoli Hua, Danwen Zheng, Jingwei Shui, Tong Zhang, Shengle Qin, Hanhong Zhang, Bo Yu, Longde Wang 等 19 位
Guangzhou University of Chinese Medicine Shenzhen Traditional Chinese Medicine Hospital Guangdong Provincial Hospital of Chinese Medicine Hainan Provincial Hospital of Traditional Chinese Medicine
阅读操作
确认中在文库中上传 PDF 后可生成中文音频讲解。
摘要与影响
Background: Fuzheng Jiedu (FZJD) granules are widely used to treat coronavirus disease (COVID-19) since their market approval, but their clinical effectiveness remains uncertain. In this study, we aimed to evaluate the effectiveness of FZJD in reducing disease progression in high-risk adults with COVID-19. Methods: A multicenter, retrospective cohort study involving high-risk adults with non-severe COVID-19 was conducted in China from May 2021 to December 2022. The study was registered at the Chinese Clinical Trial Registry (ChiCTR2200058097; https://www.chictr.org.cn/bin/project/edit?pid=160010). Patients were categorized into two groups based on the administration of FZJD granules. The outcomes included disease progression, mechanical ventilation, intensive care unit (ICU) admission, and mortality. Propensity-score analyses and multivariable regression were performed to assess the effectiveness of FZJD granules. The effectiveness was further analyzed in different subgroups. Results: A total of 1,644 patients (54.7% female patients; mean age, 62.3 years) were included, with 27.4% (451/1,644) receiving FZJD granules. After propensity score matching (PSM), 320 FZJD granule receivers and 320 non-receivers were matched. Those receiving FZJD granules were associated with lower risks of disease progression [adjusted odds ratio (OR), 0.21; 95% confidence interval (CI), 0.06-0.73], mechanical ventilation (OR, 0.15; 95% CI, 0.03-0.66), and ICU admission (OR, 0.08; 95% CI, 0.01-0.64) than those not receiving FZJD granules. The lower risk of disease progression in the FZJD group was confirmed by multivariable regression analysis and various propensity-score analyses. Furthermore, subgroup analyses demonstrated significant treatment benefits in patients with moderate COVID-19 at admission (no progression to severe disease) or in those who were not fully vaccinated (OR, 0.06; 95% CI, 0.01-0.50). Conclusion: FZJD administration was significantly associated with a reduced risk of disease progression in high-risk adults with mild-to-moderate COVID-19.
逐年被引趋势
关键指标
同类平均 = 1
同领域 · 同年份 · 同类型
Google Scholar 与 OpenAlex 的被引统计范围不同,数值存在差异属正常。
AI 辅助阅读
依据:摘要
可就本文提问;依据不足时会说明。
学术脉络
学科主题
生物医学COVID-19 Clinical Research Studies
Traditional Chinese Medicine Clinical Research · SARS-CoV-2 and COVID-19 Research
参考文献 25
此处列出前 3 条
引用本文 2
按被引量排序,此处列出前 3 条